For appointments

Call the office

Folsom, California Office: 916-983-4444

Call Now

Close

WHO:

Dr. Gish is a Hepatologist specializing in all forms of liver disease, liver cancer and liver transplant. Dr. Gish has partnered with TeleMed2U to provide telemedicine consultative services for patients with liver disease.

WHAT:

TeleMed2U is a telemedicine-based multi-specialty clinical practice increasing access to specialist providers providing, “healthcare anywhere and everywhere.” The telemedicine consultation will be conducted through our HIPAA and HITECH compliant platform. Connectivity testing will be done in advance to ensure you can connect via our telemedicine platform. Following the consultation, a clinical note will be provided including a summary of your liver consultation with Dr. Gish and his consultative recommendations.

COST:

Payment will be processed through an online secure transaction portal. The fees for consultative services are:

Initial 60 minute consultation per patient: $500.00
Follow Up 30 minute consultation per patient: $300.00

NEXT STEPS:

If you’d like to continue, please click Next to complete the form and we will contact you to schedule connectivity testing. During the test you will have the opportunity to determine the method of providing medical records, discuss appointment availability as well as discuss any additional questions that you have. If you are a healthcare facility interested in services, please complete the form and we can discuss the options that are right for you and your patients.

Email

Subject

Country

You should be aware of the general risks of transmitting information over the Internet, which may not use encryption. You should therefore not share any personal medical information that you would wish to be held confidential in a physician/patient or similar clinical relationship.

The information contained on this website is not intended, should not substitute for, or be used instead of, a clinical or therapeutic relationship with a health care professional who is fully familiar with the specifics of your case. The information on this site may assist you in your personal, general research but none of it constitutes the practice of medicine or any other health care profession.

Nothing in this site is intended as a recommendation or endorsement of any specific tests, products, procedures, healthcare provider, opinions, or other information that may be mentioned in this site. Any reliance on any information provided by the website personnel, others appearing on the site at the invitation of the website and/or other visitors to the site is solely at the user's risk.

E-mail correspondence with Dr. Robert G. Gish Consultants, LLC or any of its employees, or agents, does not create a physician/patient relationship between us or cause Dr. Gish to create or retain any medical records about you, monitor your care, or communicate with your own health care provider.

Always seek the advice of your physician or other qualified health care provider with any questions you have regarding your medical care. If you suspect that you may have a medical condition, or are seeking medical advice or treatment, we recommend that you consult a qualified health professional as soon as possible.

Powered by

Close Form

Bulevirtide Improves Health-Related Quality of Life

Nov 11, 2022

Bulevirtide Improves Health-Related Quality of Life Measured by EQ-5D VAS inPatients With Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks

AASLD nov 4-8 2022

Maria Buti1, Heiner Wedemeyer2, Soo Aleman3, Vladimir Chulanov4,5, Viacheslav Morozov6, Olga Sagalova7, Tatyana Stepanova8, Robert G Gish9, Andrew Lloyd10,

Ankita M Kaushik11, Vithika Suri11, Dmitry Manuilov11, Anu O Osinusi11, John Flaherty11, Shubhram Pandey12, Barinder Singh12, Pietro Lampertico13,14

1Hospital Universitario Valle Hebron, Barcelona, Spain; 2Medizinische Hochschule Hannover, Hannover, Germany; 3Karolinska Universitssjukhuset, Karolinska Institutet, Stockholm, Sweden; 4National Medical Research Center of Tuberculosis and Infectious Diseases, Ministry of Health, Moscow, Russian Federation; 5Sechenov University, Moscow, Russian Federation; 6Hepatolog, LLC, Samara,

Russian Federation; 7Southern Ural State Medical University, Chelyabinsk, Russian Federation; 8Clinic of Modern Medicine, Moscow, Russian Federation; 9Hepatitis B Foundation, Doylestown, PA, USA; 10Acaster Lloyd Consulting Ltd, London, UK; 11Gilead Sciences, Inc., Foster City, CA, USA; 12Pharmacoevidence Private Ltd, Punjab, India;

13Foundation Irccs Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; 14CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

References: 1. Lempp FA, et al. Nat Rev Gastroenterol Hepatol. 2016;13:580–89. 2. Buti M, et al. JHEP Rep. 2021;3:100280. 3. Hepcludex Assessment Report. European Medicines Agency; 2020. 4. Wedemeyer H, et al. J Hepatol. 2022;77(S1):S4. Abstract GS006. 5. Buti M, et al. J Hepatol. 2022;77(S1):S4. Abstract OS149. Acknowledgments: This study was funded by Gilead Sciences, Inc., Foster City, CA, USA. Medical writing and editorial support were provided by Danielle Shepherd, PhD, AlphaScientia, LLC, San Francisco, CA, USA, and funded by Gilead Sciences, Inc. Disclosures: MB declares financial relationships with Gilead Sciences, Inc., and AbbVie for speaking and teaching. HW reports Shubhra honoraria for speaking or consulting from Abbott; AbbVie; BMS; Boehringer Ingelheim; Eiger; Gilead Sciences, Inc.; Janssen; Merck Sharp & Dohme; MYR GmbH; Novartis; Novira; Roche; Roche Diagnostics; Siemens; and Transgene; and research support from Abbott; BMS; Gilead Sciences, Inc.; Novartis; Roche Diagnostics; and Roche. SA reports speaking honoraria from Gilead Sciences, Inc; AbbVie; Merck Sharp & Dohme; and Biogen; and research grants from Gilead Sciences, Inc. and AbbVie. VC reports consultancy and/or speaker’s bureau from Abbott; AbbVie; AstraZeneca; BMS; Gilead Sciences, Inc.; GSK; Hepatera; MSD/Merck; Pharmstandard; Roche; and R-Pharm. VM reports no conflicts of interest. OS reports honoraria for speaking or consulting from: AbbVie; Gilead Sciences, Inc.; Merck/Schering-Plough; Abbott; Pharmstandart; and Hepatera. TS reports no conflicts of interest. RG reports grants from Gilead Sciences, Inc.; consultancy and advisory for Abbott; AbbVie; Altimmune; Antios; Arrowhead; Dynavax; Eiger; Eisai; Enyo; Fibronostics, Inc.; Fujifilm Wako Diagnostics; Genentech; Genlantis; Gerson Lehrman Group; Gilead Sciences, Inc.; Helios; HepaTX; HepQuant; Intercept; Janssen; Merck; Perspectum; Pfizer; Quest; Sonic Incytes; Topography Health; and Venatorx; scientific or clinical advisory board for AbbVie; Antios; Dynavax; Enyo; Genentech; Genlantis; Gilead Sciences, Inc.; Helios; HepaTX; HepQuant; Intercept; Janssen; Merck; Pfizer; and Prodigy; chair clinical advisory board for Prodigy; clinical trials alliance with Topography Health; data safety monitoring board for Altimmune; Arrowhead; CymaBay Therapeutics, Inc.; and Durect; speakers bureau for AbbVie; Bristol Myers Squibb; Eisai; Genentech; Gilead Sciences, Inc.; and Intercept; minor stock shareholder in RiboSciences and CoCrystal; and stock options for AngioCrine; Eiger; Genlantis; HepaTX; and HepQuant; AL is an employee of Acaster Lloyd Consulting Ltd, London, UK, which was contracted to support this research. AK, VS, DM, AO, and JF are employees of Gilead Sciences, Inc., and may own stock or stock options. SP and BS are employees of Pharmacoevidence and report no other conflicts of interest. PL reports speaking and teaching fees from and participation in advisory committees or review panels for AbbVie; Aligos; Alnylam; Antios; Arrowhead; BMS; Eiger; Gilead Sciences, Inc.; GSK; Janssen; MSD; MYR GmbH; Roche; and Spring Bank Pharmaceuticals.

Metadata